Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy
- 23 October 2012
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 19 (9) , 1209-1212
Abstract
Recently, the disappearance of oligoclonal bands (OCBs) from the cerebrospinal fluid (CSF) of a few natalizumab-treated patients with multiple sclerosis (MS) has been reported. This is interesting since CSF-restricted OCB are believed to persist in MS. We pooled CSF data from 14 MS centers to obtain an adequate sample size for investigating the suspected changes in central nervous system (CNS)-restricted humoral immune activities in the context of natalizumab therapy. In a retrospective chart analysis, CSF parameters of blood–CSF barrier integrity and intrathecal IgG production from 73 natalizumab-treated MS patients requiring a diagnostic puncture for exclusion of progressive multifocal leukoencephalopathy were compared with CSF data obtained earlier in the course of disease before natalizumab therapy. At the time of repeat lumbar puncture, local IgG production (according to Reibergram) was significantly reduced ( p < 0.0001) and OCB had disappeared in 16% of the patients. We therefore conclude that natalizumab therapy interferes with intrathecal antibody production at least in a significant number of patients.Keywords
This publication has 10 references indexed in Scilit:
- B cells in multiple sclerosis: connecting the dotsCurrent Opinion in Immunology, 2011
- Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patientsMultiple Sclerosis Journal, 2011
- Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: Results from 211 lumbar puncturesJournal of the Neurological Sciences, 2011
- Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MSNeurology, 2011
- Changes in B- and T-Lymphocyte and Chemokine Levels With Rituximab Treatment in Multiple SclerosisArchives of Neurology, 2010
- Immune surveillance in multiple sclerosis patients treated with natalizumabAnnals of Neurology, 2006
- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Expansion of antibody reactivity in the cerebrospinal fluid of multiple sclerosis patients – follow-up and clinical implicationsFluids and Barriers of the CNS, 2005
- Cerebrospinal fluid - physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseasesMultiple Sclerosis Journal, 1998
- Flow rate of cerebrospinal fluid (CSF) — A concept common to normal blood-CSF barrier function and to dysfunction in neurological diseasesJournal of the Neurological Sciences, 1994